Can-Fite BioPharma (CANF) Tops Q1 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CANF Hot Sheet
Join SI Premium – FREE
Can-Fite BioPharma (NYSE: CANF) reported Q1 EPS of $0.00, $0.19 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $196 thousand.
For earnings history and earnings-related data on Can-Fite BioPharma (CANF) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eversource Energy (ES) Tops Q3 EPS by 18c; offers guidance
- PTC (PTC) Tops Q4 EPS by 7c
- Power Integrations (POWI) Tops Q3 EPS by 5c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
